558 related articles for article (PubMed ID: 33689790)
21. Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer's disease: preclinical proof of concept.
Maezawa I; Nguyen HM; Di Lucente J; Jenkins DP; Singh V; Hilt S; Kim K; Rangaraju S; Levey AI; Wulff H; Jin LW
Brain; 2018 Feb; 141(2):596-612. PubMed ID: 29272333
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and characterization of Pi4, a scorpion toxin from Pandinus imperator that acts on K+ channels.
M'Barek S; Mosbah A; Sandoz G; Fajloun Z; Olamendi-Portugal T; Rochat H; Sampieri F; Guijarro JI; Mansuelle P; Delepierre M; De Waard M; Sabatier JM
Eur J Biochem; 2003 Sep; 270(17):3583-92. PubMed ID: 12919322
[TBL] [Abstract][Full Text] [Related]
23. Disulfide bridge reorganization induced by proline mutations in maurotoxin.
Carlier E; Fajloun Z; Mansuelle P; Fathallah M; Mosbah A; Oughideni R; Sandoz G; Di Luccio E; Geib S; Regaya I; Brocard J; Rochat H; Darbon H; Devaux C; Sabatier JM; de Waard M
FEBS Lett; 2001 Feb; 489(2-3):202-7. PubMed ID: 11165250
[TBL] [Abstract][Full Text] [Related]
24. Induction of potassium channels in mouse brain microglia: cells acquire responsiveness to pneumococcal cell wall components during late development.
Draheim HJ; Prinz M; Weber JR; Weiser T; Kettenmann H; Hanisch UK
Neuroscience; 1999; 89(4):1379-90. PubMed ID: 10362322
[TBL] [Abstract][Full Text] [Related]
25. Structural basis of a potent peptide inhibitor designed for Kv1.3 channel, a therapeutic target of autoimmune disease.
Han S; Yi H; Yin SJ; Chen ZY; Liu H; Cao ZJ; Wu YL; Li WX
J Biol Chem; 2008 Jul; 283(27):19058-65. PubMed ID: 18480054
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of neuroprotective effects of insulin on immuno-inflammatory and systemic disorders induced by kaliotoxin, a Kv1.3 channel blocker.
Taibi-Djennah Z; Martin-Eauclaire MF; Laraba-Djebari F
Inflamm Res; 2018 Oct; 67(10):863-877. PubMed ID: 30083976
[TBL] [Abstract][Full Text] [Related]
27. Scorpion Potassium Channel-blocking Defensin Highlights a Functional Link with Neurotoxin.
Meng L; Xie Z; Zhang Q; Li Y; Yang F; Chen Z; Li W; Cao Z; Wu Y
J Biol Chem; 2016 Mar; 291(13):7097-106. PubMed ID: 26817841
[TBL] [Abstract][Full Text] [Related]
28. A selective blocker of Kv1.2 and Kv1.3 potassium channels from the venom of the scorpion Centruroides suffusus suffusus.
Corzo G; Papp F; Varga Z; Barraza O; Espino-Solis PG; Rodríguez de la Vega RC; Gaspar R; Panyi G; Possani LD
Biochem Pharmacol; 2008 Oct; 76(9):1142-54. PubMed ID: 18786511
[TBL] [Abstract][Full Text] [Related]
29. Tst26, a novel peptide blocker of Kv1.2 and Kv1.3 channels from the venom of Tityus stigmurus.
Papp F; Batista CV; Varga Z; Herceg M; Román-González SA; Gaspar R; Possani LD; Panyi G
Toxicon; 2009 Sep; 54(4):379-89. PubMed ID: 19500613
[TBL] [Abstract][Full Text] [Related]
30. An engineered scorpion toxin analogue with improved Kv1.3 selectivity displays reduced conformational flexibility.
Bartok A; Fehér K; Bodor A; Rákosi K; Tóth GK; Kövér KE; Panyi G; Varga Z
Sci Rep; 2015 Dec; 5():18397. PubMed ID: 26689143
[TBL] [Abstract][Full Text] [Related]
31. Kv1.3 channel blockade enhances the phagocytic function of RAW264.7 macrophages.
Zhu H; Yan L; Gu J; Hao W; Cao J
Sci China Life Sci; 2015 Sep; 58(9):867-75. PubMed ID: 26354506
[TBL] [Abstract][Full Text] [Related]
32. The 'functional' dyad of scorpion toxin Pi1 is not itself a prerequisite for toxin binding to the voltage-gated Kv1.2 potassium channels.
Mouhat S; Mosbah A; Visan V; Wulff H; Delepierre M; Darbon H; Grissmer S; De Waard M; Sabatier JM
Biochem J; 2004 Jan; 377(Pt 1):25-36. PubMed ID: 12962541
[TBL] [Abstract][Full Text] [Related]
33. Expression and characterization of a novel scorpine-like peptide Ev37, from the scorpion Euscorpiops validus.
Feng J; Yu C; Wang M; Li Z; Wu Y; Cao Z; Li W; He X; Han S
Protein Expr Purif; 2013 Mar; 88(1):127-33. PubMed ID: 23262394
[TBL] [Abstract][Full Text] [Related]
34. Distribution in rat brain of binding sites of kaliotoxin, a blocker of Kv1.1 and Kv1.3 alpha-subunits.
Mourre C; Chernova MN; Martin-Eauclaire MF; Bessone R; Jacquet G; Gola M; Alper SL; Crest M
J Pharmacol Exp Ther; 1999 Dec; 291(3):943-52. PubMed ID: 10565809
[TBL] [Abstract][Full Text] [Related]
35. Potassium channel Kv1.3 is highly expressed by microglia in human Alzheimer's disease.
Rangaraju S; Gearing M; Jin LW; Levey A
J Alzheimers Dis; 2015; 44(3):797-808. PubMed ID: 25362031
[TBL] [Abstract][Full Text] [Related]
36. Tityustoxin-K(alpha) blockade of the voltage-gated potassium channel Kv1.3.
Rodrigues AR; Arantes EC; Monje F; Stühmer W; Varanda WA
Br J Pharmacol; 2003 Jul; 139(6):1180-6. PubMed ID: 12871837
[TBL] [Abstract][Full Text] [Related]
37. Nuclear localization and functional characteristics of voltage-gated potassium channel Kv1.3.
Jang SH; Byun JK; Jeon WI; Choi SY; Park J; Lee BH; Yang JE; Park JB; O'Grady SM; Kim DY; Ryu PD; Joo SW; Lee SY
J Biol Chem; 2015 May; 290(20):12547-57. PubMed ID: 25829491
[TBL] [Abstract][Full Text] [Related]
38. Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation.
Beeton C; Barbaria J; Giraud P; Devaux J; Benoliel AM; Gola M; Sabatier JM; Bernard D; Crest M; Béraud E
J Immunol; 2001 Jan; 166(2):936-44. PubMed ID: 11145670
[TBL] [Abstract][Full Text] [Related]
39. Variability of Potassium Channel Blockers in Mesobuthus eupeus Scorpion Venom with Focus on Kv1.1: AN INTEGRATED TRANSCRIPTOMIC AND PROTEOMIC STUDY.
Kuzmenkov AI; Vassilevski AA; Kudryashova KS; Nekrasova OV; Peigneur S; Tytgat J; Feofanov AV; Kirpichnikov MP; Grishin EV
J Biol Chem; 2015 May; 290(19):12195-209. PubMed ID: 25792741
[TBL] [Abstract][Full Text] [Related]
40. Kv1.3 inhibition attenuates neuroinflammation through disruption of microglial calcium signaling.
Fomina AF; Nguyen HM; Wulff H
Channels (Austin); 2021 Dec; 15(1):67-78. PubMed ID: 33356832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
